PMID- 26092914
OWN - NLM
STAT- MEDLINE
DCOM- 20150922
LR  - 20220419
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 85
IP  - 2
DP  - 2015 Jul 14
TI  - International consensus diagnostic criteria for neuromyelitis optica spectrum 
      disorders.
PG  - 177-89
LID - 10.1212/WNL.0000000000001729 [doi]
AB  - Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple 
      sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G 
      antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and 
      spinal cord involvement but more restricted or more extensive CNS involvement may 
      occur. The International Panel for NMO Diagnosis (IPND) was convened to develop 
      revised diagnostic criteria using systematic literature reviews and electronic 
      surveys to facilitate consensus. The new nomenclature defines the unifying term 
      NMO spectrum disorders (NMOSD), which is stratified further by serologic testing 
      (NMOSD with or without AQP4-IgG). The core clinical characteristics required for 
      patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings 
      related to optic nerve, spinal cord, area postrema, other brainstem, 
      diencephalic, or cerebral presentations. More stringent clinical criteria, with 
      additional neuroimaging findings, are required for diagnosis of NMOSD without 
      AQP4-IgG or when serologic testing is unavailable. The IPND also proposed 
      validation strategies and achieved consensus on pediatric NMOSD diagnosis and the 
      concepts of monophasic NMOSD and opticospinal MS.
CI  - (c) 2015 American Academy of Neurology.
FAU - Wingerchuk, Dean M
AU  - Wingerchuk DM
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN. 
      wingerchuk.dean@mayo.edu weinb@mayo.edu.
FAU - Banwell, Brenda
AU  - Banwell B
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Bennett, Jeffrey L
AU  - Bennett JL
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Cabre, Philippe
AU  - Cabre P
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Carroll, William
AU  - Carroll W
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Chitnis, Tanuja
AU  - Chitnis T
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - de Seze, Jerome
AU  - de Seze J
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Fujihara, Kazuo
AU  - Fujihara K
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Greenberg, Benjamin
AU  - Greenberg B
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Jacob, Anu
AU  - Jacob A
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Jarius, Sven
AU  - Jarius S
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Lana-Peixoto, Marco
AU  - Lana-Peixoto M
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Levy, Michael
AU  - Levy M
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Simon, Jack H
AU  - Simon JH
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Tenembaum, Silvia
AU  - Tenembaum S
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Traboulsee, Anthony L
AU  - Traboulsee AL
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Waters, Patrick
AU  - Waters P
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Wellik, Kay E
AU  - Wellik KE
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
FAU - Weinshenker, Brian G
AU  - Weinshenker BG
AD  - From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), Mayo 
      Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; the 
      Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
      Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
      Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
      Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the Department 
      of Neurology (T.C.), Massachusetts General Hospital, Boston; the Department of 
      Neurology (J.d.S.), Strasbourg University, France; the Department of Multiple 
      Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of Medicine, 
      Sendai, Japan; the Departments of Neurology and Neurotherapeutics (B.G.), 
      University of Texas Southwestern Medical Center, Dallas; The Walton Centre NHS 
      Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, Department of 
      Neurology (S.J.), University Hospital Heidelberg, Germany; the Center for 
      Multiple Sclerosis Investigation (M.L.-P.), Federal University of Minas Gerais 
      Medical School, Belo Horizonte, Brazil; the Department of Neurology (M.L.), Johns 
      Hopkins University, Baltimore, MD; Portland VA Medical Center and Oregon Health 
      and Sciences University (J.H.S.), Portland; the Department of Neurology (S.T.), 
      National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina; the 
      Department of Medicine (A.L.T.), University of British Columbia, Vancouver, 
      Canada; Nuffield Department of Clinical Neurosciences (P.W.), University of 
      Oxford, UK; and the Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN. 
      wingerchuk.dean@mayo.edu weinb@mayo.edu.
CN  - International Panel for NMO Diagnosis
LA  - eng
GR  - K08 NS078555/NS/NINDS NIH HHS/United States
GR  - R01 EY022936/EY/NEI NIH HHS/United States
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, Non-U.S. Gov't
DEP - 20150619
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
CIN - Neurology. 2015 Jul 14;85(2):118-9. PMID: 26092912
CIN - Mult Scler Relat Disord. 2018 Feb;20:153. PMID: 29414289
MH  - Humans
MH  - Neuromyelitis Optica/*diagnosis
PMC - PMC4515040
EDAT- 2015/06/21 06:00
MHDA- 2015/09/24 06:00
PMCR- 2015/07/14
CRDT- 2015/06/21 06:00
PHST- 2014/09/30 00:00 [received]
PHST- 2015/01/28 00:00 [accepted]
PHST- 2015/06/21 06:00 [entrez]
PHST- 2015/06/21 06:00 [pubmed]
PHST- 2015/09/24 06:00 [medline]
PHST- 2015/07/14 00:00 [pmc-release]
AID - WNL.0000000000001729 [pii]
AID - NEUROLOGY2014621771 [pii]
AID - 10.1212/WNL.0000000000001729 [doi]
PST - ppublish
SO  - Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 
      Jun 19.